Novel Wound Healing Treatments Move Forward as French Biotech Raises €25M

Biom’up has raised €25M to develop its collagen-based powders designed to facilitate wound healing in a variety of surgeries.

Biom’up, a French biotech specializing in devices for biosurgery,  and Athyrium Capital Management have closed the first tranche of €25M bond financing to bring its surgical wound healing devices closer to a European and US market launch.

Biom’up’s devices use a collagen powder that constricts blood vessels by getting platelets in the blood to aggregate and by activating cell signaling cascades involved in blood clotting. This can help lead to hemostasis, the first step of wound healing in which bleeding stops. One device, called Hemosnowis intended to be used in surgeries that remove a woman’s ovaries and fallopian tubes. The second device, called Hemoblast Bellows, can be used in neurosurgical, ophthalmic and urological procedures.

Last year, Biom’up raised €42.5M with its IPO on Euronext Paris, and earlier this year raised €16M in another public offering.

Biom’up is joining the ranks of other European biotechs that are developing devices to improve surgery. For example, Ergomed is developing a coagulant peptidePolyganics is developing a polymer-based sealant patch and Gecko Biomedical recently got approval for a light-sensitive surgical glue.


Images by amab/Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.